Influenza Clinical Trial
— CSL's IVVOfficial title:
A Phase IV, Randomized, Observer-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in Adults Aged ≥ 18 to < 65 Years.
Verified date | October 2017 |
Source | Seqirus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will assess the Efficacy, Safety and Tolerability profile of CSL's Influenza Vaccine administered intramuscularly against laboratory-confirmed influenza illness in a population defined as being not at risk of severe complications following influenza infection.
Status | Completed |
Enrollment | 7500 |
Est. completion date | January 2010 |
Est. primary completion date | November 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility |
Inclusion Criteria: - Healthy males and females aged = 18 to < 65 years at the time of vaccination - Non pregnant/ non lactating females Exclusion Criteria: - Hypersensitivity to influenza vaccine or allergy to any components of the Study Vaccines - Vaccination against influenza in the previous 6 months - Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality - Known history of Guillain-Barré Syndrome; - Clinical signs of active infection and/or an oral temperature of = 37.8 oC. - History of neurological disorders or seizures - Confirmed or suspected immunosuppressive condition or a previously diagnosed immunodeficiency disorder - Current or recent immunosuppressive or immunomodulative therapy, including systemic corticosteroids - Administration of immunoglobulins and/or any blood products; - Participation in a clinical trial or use of an investigational compound; - Vaccination with a registered vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior; - Participants indicated to receive an influenza vaccine on an annual basis according to the local public health recommendations. |
Country | Name | City | State |
---|---|---|---|
Australia | CMAX, a division of IDT Australia | Adelaide | South Australia |
Australia | Paediatric Trials Unit, Women's and Children's Hospital | Adelaide | South Australia |
Australia | Australian Clinical Research Organisation | Auchenflower | Queensland |
Australia | Trialworks Clinical Research Services | Brisbane | Queensland |
Australia | Australian Clinical Research Organisation | Brookvale | New South Wales |
Australia | Australian Clinical Research Organisation Caboolture Clinical Research Centre | Caboolture | Queensland |
Australia | School of Medicine, James Cook University, Cairns Base Hospital | Cairns | Queensland |
Australia | The Clinical Trials Unit, Canberra Hospital | Canberra | Australian Capital Territory |
Australia | Australian Clinical Research Organisation | Caringbah | New South Wales |
Australia | Barwon Health, Geelong Hospital | Geelong | Victoria |
Australia | Gold Coast Hospital | Gold Coast | Queensland |
Australia | Sexual Health Service | Hobart | Tasmania |
Australia | Australian Clinical Research Organisation | Kippa Ring | Queensland |
Australia | Emeritus Research | Malvern East | Victoria |
Australia | Murdoch Childrens Research Institute | Melbourne | Victoria |
Australia | Lung Institute of Western Australia | Perth | Western Australia |
Australia | Princess Margaret Hospital for Children | Perth | Western Australia |
Australia | Eastern Area Health Service, Prince of Wales Hospital | Randwick | New South Wales |
Australia | Primary Old Port Road Medical and Dental Centre | Royal Park | South Australia |
Australia | National Centre for Immunisation Research & Surveillance (NCIRS) The Children's Hospital at Westmead | Westmead | New South Wales |
New Zealand | Auckland Clinical Studies | Auckland | |
New Zealand | 198 Youth Health Centre | Christchurch | |
New Zealand | Southern Clinical Trials | Christchurch | |
New Zealand | RMC Medical Centre | Dunedin |
Lead Sponsor | Collaborator |
---|---|
Seqirus |
Australia, New Zealand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | CSL's IVV Overall Vaccine Efficacy (VE) Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection | Incidence of Laboratory Confirmed Influenza A/B infection was assessed per the study population in the 2008 and 2009 Southern Hemisphere influenza seasons. Vaccine efficacy = 100 x (1 - ratio of incidence rate). Ratio of incidence rate = active Study Vaccine recipient infection rate / placebo recipient infection rate. |
2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009 | |
Secondary | CSL's IVV Vaccine Efficacy Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection Due to Strains Matched to Vaccine Strains | Incidence of laboratory confirmed influenza A/B infection due to strains matched to vaccine strains was assessed per the study population in the 2008 and 2009 Southern Hemisphere influenza seasons. Vaccine efficacy = 100 x (1 - ratio of incidence rate). Ratio of incidence rate = active Study Vaccine recipient infection rate / Placebo recipient infection rate. |
2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009 | |
Secondary | Incidence of Influenza-like Illness (ILI) | The criteria for the protocol defined ILI were as follows: At least one respiratory symptom: cough, sore throat or nasal congestion And at least one systemic symptom: fever (as defined by oral temperature = 37.8°C (100.0°F), or feverishness (as defined by participant's subjective feeling of fever), chills or body aches. The CDC ILI case definition was the occurrence of fever (100°F [37.8°C] or higher) in conjunction with either cough or sore throat. |
2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009 | |
Secondary | Percentage of Participants With a Minimum Post-vaccination Hemagglutination Inhibition (HI) Titer of 1:40, Year 2008 | 21 days after study vaccination | ||
Secondary | Percentage of Participants With a Minimum Post-vaccination Hemagglutination Inhibition (HI) Titer of 1:40, Year 2009 | 21 days after study vaccination | ||
Secondary | Percentage of Participants With Seroconversion 21 Days After Study Vaccination, Year 2008 | Seroconversion rate: defined as the percentage of participants with either a pre-vaccination HI titer < 1:10 and a post-vaccination HI titer = 1:40 or a pre-vaccination titer = 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer. | 21 days after study vaccination | |
Secondary | Percentage of Participants With Seroconversion 21 Days After Study Vaccination, Year 2009 | Seroconversion rate: defined as the percentage of participants with either a pre-vaccination HI titer < 1:10 and a post-vaccination HI titer = 1:40 or a pre-vaccination titer = 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer. | 21 days after study vaccination | |
Secondary | Geometric Mean Fold Increase in HI Titer 21 Days After Study Vaccination, Year 2008 | Geometric mean fold increase in HI titer was defined as the geometric mean titer (GMT) after vaccination divided by the GMT before vaccination. | 21 days after study vaccination | |
Secondary | Geometric Mean Fold Increase in HI Titer Rate 21 Days After Study Vaccination, Year 2009 | Geometric mean fold increase in HI titer was defined as the geometric mean titer (GMT) after vaccination divided by the GMT before vaccination. | 21 days after study vaccination | |
Secondary | Frequency and Intensity of Local and Systemic Solicited Symptoms | Adverse event grading: Grade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities. Grade 2 (moderate): Discomfort was enough to cause some interference with daily activities. Grade 3 (severe): Symptoms that prevented normal, everyday activities. Fever Grade 1: = 37.7°C - < 38.0°C (= 99.9 - < 100.4°F) Grade 2: = 38.0°C - < 39.0°C (= 100.4 - < 102.2°F) Grade 3: = 39.0°C (> 102.2°F) |
5 days after study vaccination | |
Secondary | Frequency and Intensity of Unsolicited Adverse Events (UAEs) | UAE grading: Grade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities. Grade 2 (moderate): Discomfort was enough to cause some interference with daily activities. Grade 3 (severe): Symptoms that prevented normal, everyday activities. |
21 days after study vaccination | |
Secondary | Serious Adverse Events (SAEs) | An SAE was any untoward medical occurrence that at any dose: Resulted in death; Was life-threatening; Required an unexpected in-participant hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability / incapacity; Was a congenital anomaly / birth defect; and / or Was medically significant (defined as an event that did not necessarily meet any of the SAE criteria, but was judged by the treating physician to potentially jeopardize the participant or require medical intervention to prevent one of the out |
180 days after study vaccination | |
Secondary | New Onsets of Chronic Illness (NOCI) | An NOCI was defined as the diagnosis of a chronic medical condition where the symptoms commenced or worsened following exposure to study vaccine and may have included those potentially controllable by medication (e.g., glaucoma, hypertension). | 180 days after study vaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |